Pathophysiological networks and targeted approaches for prevention and treatment of cGvHD. FDA-approved drugs are highlighted within red bubbles. Ag, antigen; AKT, Ak strain transforming; BAFF, B-cell activating factor; BAFF R, BAFF receptor; BCR, B-cell receptor; BLNK, B-cell linker; BTK, Bruton’s Tyrosine Kinase; BTK/ITK, Bruton’s Tyrosine Kinase /IL-2 Inducible T-cell Kinase; CD, cluster of differentiation; FOXP3, forkhead box P3; HSP47, heat shock protein 47; INF-γ, interferon gamma; ITK, IL-2-inducible T-cell kinase; Jakinibs, Janus kinase inhibitors; JAKs, Janus kinases; LCK, lymphocyte-specific protein tyrosine kinase; NOTCH2, Neurogenic locus notch homolog protein 2; NOTCH2 mAb, neurogenic locus notch homolog protein 2 mAb; PI3K, phosphoinositide 3-kinase; pSTAT5, phosphorylated signal transducer and activator of transcription 5; ROCK2, Rho associated coiled-coil containing protein kinase 2; STATs, signal transducers and activators of transcription; SYK, spleen associated tyrosine kinase; TCR, T-cell receptor; TGF-β, transforming growth factor beta; Th, T helper; TNF-α, tumor necrosis factor alpha; Treg, T regulatory cell; VA-lip HSP47, vitamin A coupled liposomal containing small interfering RNA (siRNA) against heat shock protein 47.